Search

Your search keyword '"Bruzek, Debra"' showing total 28 results
Start Over Author "Bruzek, Debra"
28 results on '"Bruzek, Debra"'

17. Hybritech Total and Free Prostate-specific Antigen Assays Developed for the Beckman Coulter Access Automated Chemiluminescent Immunoassay System: A Multicenter Evaluation of Analytical Performance

Author

Laffin, Robert J, primary, Chan, Daniel W, primary, Tanasijevic, Milenko J, primary, Fischer, George A, primary, Markus, Wayne, primary, Miller, Joan, primary, Matarrese, Pat, primary, Sokoll, Lori J, primary, Bruzek, Debra J, primary, Eneman, Julie, primary, Nelson, Janice, primary, Bray, Kurtis R, primary, Huang, Jay, primary, and Loveland, Kathleen G, primary

Published
2001
Full Text
View/download PDF

21. Bayer immuno 1™ PSA assay: An automated, ultrasensitive method to quantitate total PSA in serum

Author

Morris, Deborah L., primary, Dillon, Paul W., additional, Very, Donald L., additional, Ng, Phillip, additional, Kish, Linda, additional, Goldblatt, Joan L., additional, Bruzek, Debra J., additional, Chan, Daniel W., additional, Ahmed, M. Saber, additional, Witek, Deborah, additional, Fritsche, Herbert A., additional, Smith, Carol, additional, Schwartz, Delia, additional, Schwartz, Morton K., additional, Noteboom, Jennifer L., additional, Vessella, Robert L., additional, Yeung, Kwok K., additional, and Allard, W. Jeffrey, additional

Published
1998
Full Text
View/download PDF

22. Clinical Evaluation Comparing AxSYM® CA 15-3TM, IMx® CA 15-3 and Truquant® BRTM RIA

Author

Lynch, Don M., primary, Rogers, Patrick E., additional, Love, Jessica C., additional, Salkas, Michael J., additional, Skarphol, Kelly A., additional, Gross, Mary E., additional, Lu, Michael G., additional, Petrides, Victoria H., additional, Bruzek, Debra J., additional, Cox, Jennifer L., additional, Jones, Kerrie A., additional, Kelley, Cynthia A., additional, and Chan, Daniel W., additional

Published
1998
Full Text
View/download PDF

24. Clinical Evaluation Comparing AxSYM® CA 15-3TM, IMx® CA 15-3 and Truquant® BRTM RIA.

Author

Lynch, Don M., Rogers, Patrick E., Love, Jessica C., Salkas, Michael J., Skarphol, Kelly A., Gross, Mary E., Lu, Michael G., Petrides, Victoria H., Bruzek, Debra J., Cox, Jennifer L., Jones, Kerrie A., Kelley, Cynthia A., and Chan, Daniel W.

Abstract

A retrospective clinical study was conducted to compare results obtained by AxSYM® CA 15-3TM, IMx® CA 15-3 and Truquant® BRTM RIA using surplus serum specimens from healthy volunteers and patients with benign and malignant diseases. Linear regression analysis of AxSYM and IMx CA 15-3 versus Truquant BR RIA for specimens with results 0-250 U/ml gave correlation coefficients of 0.888 and 0.910 and slopes of 0.67 and 0.69, respectively. For specimens with results 0-2,000 U/ml, slopes were 0.95 and 0.91, respectively. Receiver operator characteristic analyses, based on results from healthy females plus nonmalignant disease patients versus breast cancer patients, for all three assays gave essentially equivalent areas under the curves. Concordance between AxSYM or IMx CA 15-3 and Truquant BR RIA was greater than 92%. Serial dilution of seven serum specimens yielded linear regression correlation coefficients ranging from 0.997 to 1.000 for AxSYM and IMx CA 15-3, and from 0.962 to 0.998 for Truquant BR RIA. The average percent CVs of the calculated assay values for the 7 specimens were 4.9, 2.7 and 18.1 for AxSYM CA 15-3, IMx CA 15-3 and Truquant BR RIA, respectively. Average percent recoveries ranged from 96.2 to 110.7 for AxSYM and IMx CA 15-3, and 81.8 to 93.3 for Truquant BR RIA. Although assay values differ between the two methodologies, AxSYM CA 15-3, IMx CA 15-3 and Truquant BR RIA showed comparable trending results for the 24 breast cancer patients evaluated for serial monitoring. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

25. Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical Prostatectomy

Author

Oesterling, Joseph E., Chan, Daniel W., Epstein, Jonathan I., Kimball, Allyn W., Bruzek, Debra J., Rock, Robert C., Brendler, Charles B., and Walsh, Patrick C.

Abstract

The usefulness of prostate specific antigen to predict final pathological stage was studied in 178 consecutive patients. Prostate specific antigen was determined preoperatively in all patients by a monoclonal immunoradiometric assay. All pathological specimens were examined for capsular penetration, seminal vesicle involvement and lymph node involvement. Prostate specific antigen correlated directly with capsular penetration (p less than 0.002), seminal vesicle involvement (p less than 0.02) and lymph node involvement (p less than 0.05). However the diagnostic accuracy of an elevated serum antigen level on an individual basis was only 55 per cent for capsular penetration and 50 per cent for seminal vesicle involvement and lymph node involvement.

Published
1988
Full Text
View/download PDF

26. Clinical Evaluation Comparing AxSYM®CA 15-3TM, IMx®CA 15-3 and Truquant®BRTMRIA

Author

Lynch, Don M., Rogers, Patrick E., Love, Jessica C., Salkas, Michael J., Skarphol, Kelly A., Gross, Mary E., Lu, Michael G., Petrides, Victoria H., Bruzek, Debra J., Cox, Jennifer L., Jones, Kerrie A., Kelley, Cynthia A., and Chan, Daniel W.

Abstract

A retrospective clinical study was conducted to compare results obtained by AxSYM® CA 15-3TM, IMx® CA 15-3 and Truquant® BRTM RIA using surplus serum specimens from healthy volunteers and patients with benign and malignant diseases. Linear regression analysis of AxSYM and IMx CA 15-3 versus Truquant BR RIA for specimens with results 0–250 U/ml gave correlation coefficients of 0.888 and 0.910 and slopes of 0.67 and 0.69, respectively. For specimens with results 0–2,000 U/ml, slopes were 0.95 and 0.91, respectively. Receiver operator characteristic analyses, based on results from healthy females plus nonmalignant disease patients versus breast cancer patients, for all three assays gave essentially equivalent areas under the curves. Concordance between AxSYM or IMx CA 15-3 and Truquant BR RIA was greater than 92%. Serial dilution of seven serum specimens yielded linear regression correlation coefficients ranging from 0.997 to 1.000 for AxSYM and IMx CA 15-3, and from 0.962 to 0.998 for Truquant BR RIA. The average percent CVs of the calculated assay values for the 7 specimens were 4.9, 2.7 and 18.1 for AxSYM CA 15-3, IMx CA 15-3 and Truquant BR RIA, respectively. Average percent recoveries ranged from 96.2 to 110.7 for AxSYM and IMx CA 15-3, and 81.8 to 93.3 for Truquant BR RIA. Although assay values differ between the two methodologies, AxSYM CA 15-3, IMx CA 15-3 and Truquant BR RIA showed comparable trending results for the 24 breast cancer patients evaluated for serial monitoring.

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results